Following ASH Conference, Vetr Upgrades Celgene

Loading...
Loading...

The Vetr crowd upgraded their rating for Celgene Corporation CELG from 4.5 stars (Buy), issued two days ago, to 5 stars (Strong). Crowd sentiment is generally positive, with 66 percent of Vetr user ratings bullish.

Coming on the heels of the annual American Society of Hematology conference (ASH). Clelgene's announcements at ASH included promising results in several early studies investigating a treatment for blood cell-inhibiting syndromes such as lukemia.

Late in November, the biopharma company also received a nod from Oppenheimer, who initiated coverage of the stock at Outperform.

See how crowdsourced ratings could help you time the market.

Currently, Vetr's average crowd users target price for the stock is up at $131.21, which is below the average analyst target price of $138.36. Less than 2 percent of Vetr users are holding T in their watch lists.

Posted In: UpgradesHealth CareCrowdsourcingAnalyst RatingsVetr
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...